Table 1 Clinical characteristics of the study patients stratified according to 30-day mortality.
Variable | Total (N = 842) | 30-day mortality | ||
|---|---|---|---|---|
Survival (N = 757) | Death (N = 85) | p-value | ||
Male sex (N, %) | 667 (79.22) | 610 (80.58) | 57 (67.06) | 0.004* |
Body mass index (kg/m²) | 24.20 ± 3.45 | 24.26 ± 3.41 | 23.69 ± 3.76 | 0.154 |
Use of LMWH (N, %) | 18 (2.14) | 17 (2.25) | 1 (1.18) | 0.999 |
Use of unfractionated heparin (N, %) | 836 (99.29) | 754 (99.60) | 82 (96.47) | 0.016* |
GRACE score (point) | 169.70 ± 46.75 | 163.47 ± 43.55 | 225.20 ± 36.64 | <0.001* |
Age (years) | 63.39 ± 13.24 | 62.49 ± 13.18 | 71.42 ± 10.96 | <0.001* |
Heart rate (/min) | 81.06 ± 26.41 | 80.98 ± 23.88 | 81.85 ± 43.04 | 0.855 |
SBP (mmHg) | 126.57 ± 38.71 | 130.03 ± 35.60 | 95.68 ± 50.24 | <0.001* |
Creatinine (mg/dL) | 1.24 ± 1.22 | 1.19 ± 1.14 | 1.74 ± 1.71 | 0.005* |
Troponin-T (pg/mL) | 673.02 ± 1650.60 | 536.57 ± 1366.20 | 1886.62 ± 2968.29 | <0.001* |
Arrest on admission (N, %) | 22 (2.61) | 10 (1.32) | 12 (14.12) | <0.001* |
Killip class | <0.001* | |||
I (N, %) | 380 (45.13) | 369 (48.75) | 11 (12.94) | |
II (N, %) | 164 (19.48) | 159 (21.00) | 5 (5.88) | |
III (N, %) | 125 (14.85) | 101 (13.34) | 24 (28.24) | |
IV (N, %) | 173 (20.55) | 128 (16.91) | 45 (52.94) | |
Clinical measurements | ||||
LVEF (%) | 45.26 ± 12.31 | 46.98 ± 11.01 | 29.58 ± 12.52 | <0.001* |
NT-proBNP (pg/mL) | 3123.6 ± 8133.8 | 2459.9 ± 7140.7 | 9029.6 ± 12815.3 | <0.001* |
Creatine kinase-MB (ng/mL) | 28.53 ± 67.43 | 24.62 ± 58.07 | 63.32 ± 117.52 | 0.004* |
White blood cell count (10^3/μL) | 11.47 ± 4.03 | 11.36 ± 3.93 | 12.43 ± 4.74 | 0.049* |
Neutrophil ratio (%) | 65.04 ± 17.05 | 64.79 ± 16.74 | 67.28 ± 19.59 | 0.262 |
hs-CRP (mg/L) | 25.10 ± 54.34 | 24.26 ± 54.82 | 33.19 ± 49.17 | 0.173 |
aPTT (s) | 35.64 ± 28.79 | 35.00 ± 27.60 | 41.28 ± 37.47 | 0.137 |
Platelets (10^3/μL) | 244.31 ± 81.84 | 246.15 ± 80.56 | 227.94 ± 91.33 | 0.052 |
Total cholesterol (mg/dL) | 186.16 ± 47.58 | 187.99 ± 47.51 | 169.90 ± 45.29 | <0.001* |
Triglyceride (mg/dL) | 115.63 ± 103.35 | 117.23 ± 106.26 | 97.88 ± 60.35 | 0.022* |
Glucose (mg/dL) | 196.38 ± 94.15 | 190.34 ± 88.76 | 250.26 ± 120.70 | <0.001* |
Medical History | ||||
Hypertension (N, %) | 434 (51.54) | 388 (51.25) | 46 (54.12) | 0.617 |
Diabetes mellitus (N, %) | 232 (27.59) | 199 (26.32) | 33 (38.82) | 0.015* |
COPD (N, %) | 17 (2.02) | 15 (1.98) | 2 (2.35) | 0.686 |
Hyperlipidaemia (N, %) | 94 (11.16) | 89 (11.76) | 5 (5.88) | 0.103 |
History of PCI (N, %) | 106 (12.59) | 96 (12.68) | 10 (11.76) | 0.809 |
CAOD (N, %) | 145 (17.22) | 124 (16.38) | 21 (24.71) | 0.054 |
Heart failure (N, %) | 21 (2.49) | 18 (2.38) | 3 (3.53) | 0.461 |
Arrhythmia (N, %) | 20 (2.38) | 19 (2.51) | 1 (1.18) | 0.711 |
Stroke (N, %) | 43 (5.11) | 31 (4.10) | 12 (14.12) | <0.001* |
PAOD (N, %) | 11 (1.31) | 9 (1.19) | 2 (2.35) | 0.307 |
Malignancy (N, %) | 46 (5.46) | 37 (4.89) | 9 (10.59) | 0.041* |
Chronic kidney disease (N, %) | 44 (5.23) | 35 (4.62) | 9 (10.59) | 0.034* |
Chronic liver disease (N, %) | 7 (0.83) | 6 (0.79) | 1 (1.18) | 0.527 |
Procedural characteristics | ||||
Door-to-balloon time (min) | 64.62 ± 32.55 | 63.39 ± 31.68 | 75.51 ± 37.99 | 0.006* |
Procedure time (min) | 40.50 ± 20.44 | 39.62 ± 19.97 | 48.31 ± 22.94 | <0.001* |
Type of contrast medium | 0.217 | |||
Iopamidol (N, %) | 198 (23.52) | 177 (23.38) | 21 (24.71) | |
Iodixanol (N, %) | 642 (76.25) | 579 (76.49) | 63 (74.12) | |
Iopromide (N, %) | 2 (0.24) | 1 (0.13) | 1 (1.18) | |
Contrast volume (mL) | 192.74 ± 76.01 | 193.32 ± 76.04 | 187.65 ± 76.01 | 0.515 |
Multivessel disease (N, %) | 515 (61.16) | 452 (59.71) | 63 (74.12) | 0.01* |
LM involvement (N, %) | 38 (4.51) | 28 (3.70) | 10 (11.76) | 0.003* |
DNI Time-0 (%) | 0.78 ± 1.79 | 0.68 ± 1.58 | 1.66 ± 2.99 | 0.004* |
DNI Time-I (%) | 2.23 ± 5.24 | 1.30 ± 2.52 | 10.84 ± 11.96 | <0.001* |
DNI Time-24 (%) | 2.47 ± 6.82 | 1.33 ± 2.58 | 15.65 ± 17.98 | <0.001* |
